Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6250-6258

  Huang, Jianping ^a   Jochems, Caroline ^a   Anderson, Austin M ^a   Talaie, Tara ^a   Jales, Alessandra ^a   Madan, Ravi A ^a   Hodge, James W ^a   Tsang, Kwong Y ^a   Liewehr, David J ^a   Steinberg, Seth M ^a   Gulley, James L ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD27 ANTIGEN; IPILIMUMAB; MYOSIN IIA; RILIMOGENE GALVACIREPVEC;

ARTICLE; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGENS, CD27; CANCER VACCINES; CELL SEPARATION; CLINICAL TRIALS AS TOPIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; MALE; PROSTATIC NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84879110254     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300022     Document Type: Article

References (36)

1. Nolte, M. A., R. W. van Olffen, K. P. van Gisbergen, and R. A. van Lier. 2009. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229: 216-231.
2. Lens, S. M., K. Tesselaar, M. H. van Oers, and R. A. van Lier. 1998. Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol. 10: 491-499. (Pubitemid 28564378)
3. Hintzen, R. Q., S. M. Lens, G. Koopman, S. T. Pals, H. Spits, and R. A. van Lier. 1994. CD70 represents the human ligand for CD27. Int. Immunol. 6: 477-480. (Pubitemid 24087241)
4. Tesselaar, K., L. A. Gravestein, G. M. van Schijndel, J. Borst, and R. A. van Lier. 1997. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J. Immunol. 159: 4959-4965. (Pubitemid 127471033)
5. Tesselaar, K., Y. Xiao, R. Arens, G. M. van Schijndel, D. H. Schuurhuis, R. E. Mebius, J. Borst, and R. A. van Lier. 2003. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170: 33-40.
6. van Oosterwijk, M. F., H. Juwana, R. Arens, K. Tesselaar, M. H. van Oers, E. Eldering, and R. A. van Lier. 2007. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int. Immunol. 19: 713-718.
7. Vardouli, L., C. Lindqvist, K. Vlahou, A. S. Loskog, and A. G. Eliopoulos. 2009. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther. 16: 848-860.
8. Huang, J., H. T. Khong, M. E. Dudley, M. El-Gamil, Y. F. Li, S. A. Rosenberg, and P. F. Robbins. 2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28: 258-267. (Pubitemid 40593992)
9. Huang, J., K. W. Kerstann, M. Ahmadzadeh, Y. F. Li, M. El-Gamil, S. A. Rosenberg, and P. F. Robbins. 2006. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J. Immunol. 176: 7726-7735. (Pubitemid 43849073)
10. Levine, S. J. 2008. Molecular mechanisms of soluble cytokine receptor generation. J. Biol. Chem. 283: 14177-14181.
11. Heaney, M. L., and D. W. Golde. 1998. Soluble receptors in human disease. J. Leukoc. Biol. 64: 135-146. (Pubitemid 28354974)
12. Vonderheide, R. H., J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, et al. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19: 3280-3287. (Pubitemid 32591446)
13. Huang, J., C. Jochems, T. Talaie, A. Anderson, A. Jales, K. Y. Tsang, R. A. Madan, J. L. Gulley, and J. Schlom. 2012. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 120: 3030-3038.
14. Glouchkova, L., B. Ackermann, A. Zibert, R. Meisel, M. Siepermann, G. E. Janka-Schaub, U. Goebel, A. Troeger, and D. Dilloo. 2009. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J. Immunol. 182: 718-725.
15. Kato, K., P. Chu, S. Takahashi, H. Hamada, and T. J. Kipps. 2007. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp. Hematol. 35: 434-442.
16. Loenen, W. A., E. De Vries, L. A. Gravestein, R. Q. Hintzen, R. A. Van Lier, and J. Borst. 1992. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur. J. Immunol. 22: 447-455.
17. Hintzen, R. Q., R. de Jong, C. E. Hack, M. Chamuleau, E. F. de Vries, I. J. ten Berge, J. Borst, and R. A. van Lier. 1991. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J. Immunol. 147: 29-35.
18. Font, J., L. Pallares, J. Martorell, E. Martinez, A. Gaya, J. Vives, and M. Ingelmo. 1996. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 81: 239-243.
19. van Oers, M. H., S. T. Pals, L. M. Evers, C. E. van der Schoot, G. Koopman, J. M. Bonfrer, R. Q. Hintzen, A. E. von dem Borne, and R. A. van Lier. 1993. Expression and release of CD27 in human B-cell malignancies. Blood 82: 3430-3436.
20. Ciccarelli, B. T., G. Yang, E. Hatjiharissi, L. Ioakimidis, C. J. Patterson, R. J. Manning, L. Xu, X. Liu, H. Tseng, P. Gong, et al. 2009. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Clin. Lymphoma Myeloma 9: 56-58.
21. De Milito, A., S. Aleman, R. Marenzi, A. Sonnerborg, D. Fuchs, M. Zazzi, and F. Chiodi. 2002. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clin. Exp. Immunol. 127: 486-494. (Pubitemid 34437820)
22. Madan, R. A., J. L. Gulley, J. Schlom, S. M. Steinberg, D. J. Liewehr, W. L. Dahut, and P. M. Arlen. 2008. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res. 14: 4526-4531.
23. Madan, R. A., M. Mohebtash, P. M. Arlen, M. Vergati, M. Rauckhorst, S. M. Steinberg, K. Y. Tsang, D. J. Poole, H. L. Parnes, J. J. Wright, et al. 2012. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13: 501-508.
24. Zofall, M., T. Fischer, K. Zhang, M. Zhou, B. Cui, T. D. Veenstra, and S. I. S. Grewal. 2009. Histone H2A.Z cooperates with RNAi and heterochromatin factors to suppress antisense RNAs. Nature 461: 419-422.
25. de Jong, R., W. A. Loenen, M. Brouwer, L. van Emmerik, E. F. de Vries, J. Borst, and R. A. van Lier. 1991. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J. Immunol. 146: 2488-2494.
26. Kantoff, P. W., T. J. Schuetz, B. A. Blumenstein, L. M. Glode, D. L. Bilhartz, M. Wyand, K. Manson, D. L. Panicali, R. Laus, J. Schlom, et al. 2010. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28: 1099-1105.
27. Hodi, F. S., M. C. Mihm, R. J. Soiffer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100: 4712-4717. (Pubitemid 36457795)
28. Downey, S. G., J. A. Klapper, F. O. Smith, J. C. Yang, R. M. Sherry, R. E. Royal, U. S. Kammula, M. S. Hughes, T. E. Allen, C. L. Levy, et al. 2007. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13: 6681-6688. (Pubitemid 350206804)
29. Agematsu, K., T. Kobata, K. Sugita, G. J. Freeman, M. P. Beckmann, S. F. Schlossman, and C. Morimoto. 1994. Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J. Immunol. 153: 1421-1429. (Pubitemid 24251087)
30. Dang, L. V. P., A. Nilsson, H. Ingelman-Sundberg, A. Cagigi, L. B. S. Gelinck, K. Titanji, A. De Milito, S. Grutzmeier, J. Hedlund, F. P. Kroon, and F. Chiodi. 2012. Soluble CD27 induces IgG production through activation of antigen-primed B cells. J. Intern. Med. 271: 282-293.
31. Kim, P. S., and R. Ahmed. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22: 223-230.
32. Halstead, E. S., Y. M. Mueller, J. D. Altman, and P. D. Katsikis. 2002. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat. Immunol. 3: 536-541.
33. Wilcox, R. A., D. B. Flies, G. Zhu, A. J. Johnson, K. Tamada, A. I. Chapoval, S. E. Strome, L. R. Pease, and L. Chen. 2002. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109: 651-659. (Pubitemid 34204844)
34. Ilani, T., G. Vasiliver-Shamis, S. Vardhana, A. Bretscher, and M. L. Dustin. 2009. T cell antigen receptor signaling and immunological synapse stability require myosin IIA. Nat. Immunol. 10: 531-539.
35. Yu, Y., N. C. Fay, A. A. Smoligovets, H.-J. Wu, and J. T. Groves. 2012. Myosin IIA modulates T cell receptor transport and CasL phosphorylation during early immunological synapse formation. PLoS ONE 7: e30704.
36. Prasad, K. V. S., Z. Ao, Y. Yoon, M. X. Wu, M. Rizk, S. Jacquot, and S. F. Schlossman. 1997. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc. Natl. Acad. Sci. USA 94: 6346-6351.